• Contact Us

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Coming Soon – Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target
      • Kinase Assays
      • ATPase Assays
      • cGAS Assays
      • Glycosyltransferase Assays
      • Phosphodiesterase Assays
      • Ligase and Synthetase Assay
      • Methyltransferase Assay Kits
      • GTPase Assays
      • GAP Assays
      • GEF Assays
    • Ordering Information
  • Therapeutics
    • Pipeline
    • Scientific Advisory Board
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Residence Time Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
  • Blog
  • MY CART
    No products in cart.

Blog

Killing Two Kinases with One Drug

by Abid / Thursday, 26 March 2015 / Published in HTS Assays

Cancer cells are characterized by a complex network of interrelated and compensatory signaling driving multiple kinases that reduce their sensitivity to targeted therapy. Strategies that inhibit two or more kinases are needed to block the growth of refractory tumor cells. Researchers at McGill University (Canada), led by Dr. Suman Rao at the Cancer Drug Research Laboratory in the Division of Medical Oncology at McGill University Health Center, created a novel strategy to promote sustained inhibition of two oncogenic kinases.

twokinases

Clinical attrition rates for multi-targeted agents are significantly lower than those of single-targeted agents, however rational design of multi-targeted drugs is very challenging. Most efforts to inhibit multiple kinases has relied on single chemical scaffolds with overlapping specificity, sometimes called “dirty drugs.” The McGill group used a more rational approach by linking two different, highly selective drugs to produce a single “combi-molecule.” Such combi-molecules can exert their actions as a single molecule or as pro-drugs that cleaved in the cell to produce the two separate inhibitors.

In their recent study in PLOS One, Dr. Rao and colleagues created a combi-molecule for tandem blockage of two tyrosine kinases using highly selective inhibitors for the epidermal growth factor receptor (EGFR) and c-Src, which have synergistic effects on tumor growth and progression. Optimization of the linker group led resulted in discovery of AL776, which showed potent inhibition of both targets in in vitro kinase assays (IC50 EGFR = 0.12 µM and IC50 c-Src = 3 nM). They next demonstrated that the combi-molecule potently inhibited growth and invasion and induced apoptosis in cancer cells. Lastly, they demonstrated that AL776 blocked auto-phosphorylation of both kinases and a downstream target in a mouse tumor model and strongly inhibited tumor growth. The combi-molecule was incompletely hydrolyzed to the two separate inhibitors in cells and in vivo and most likely exerts its effects as a combination of the three species.

This study provides proof of concept for the rational combi-molecule approach for multi-targeted therapies, which has great potential for extension to other targets given the number and diversity of existing kinase inhibitors


Learn more about the Transcreener® ADP² Kinase Assay, the ONLY direct ADP detection method available for ATPase and Kinase Assays.

Tagged under: Transcreener ADP Kinase Assay

What you can read next

HSP90 Inhibitor Immunotherapy
Enhancing Checkpoint Blockade Immunotherapy: Sensitizing Tumors with HSP90 Inhibitors
Doubling the Odds: Two-Pronged Strategy to Halt Cancer Cell Proliferation
Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part II

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2019

    BellBrook Labs Recap of SLAS 2019 in Washington DC.

    BellBrook Labs will be exhibiting and have post...
  • What is a kinase assay

    How Does a Biochemical Kinase Assay Work?

    A kinase assay works by simply measuring the ac...
  • Lupus NIK Inhibitor

    Transcreener ADP Assay Enables Evaluation of NIK Inhibitors in Lupus Drug Discovery

      Systemic lupus erythematosus (SLE), or l...
  • Histone Methylation PRMT4

    Sensitive Methyltransferase Assay Proves Successful with PRMT4

    Histone methyltransferases (HMTs) play a critic...
  • Acetyl CoA Carboxylase Inhibitors

    Acetyl-CoA Carboxylase Inhibitors: Transcreener ADP Assay Powers Drug Detection Strategy

    The impact of Acetyl-CoA carboxylases (ACCs) on...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA

(608) 443-2400

info@bellbrooklabs.com

Powered by Digital Fitness | Copyright © 2018 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP